NSE ScannerHospitals & Diagnostics · Medical/Nursing Services · NSE: LOTUSEYE · data 2026-10-31
Lotus Eye Hospital And Institute Ltd
In plain words
Price: 25.7% below its 52-week high of ₹147.
Delivery: 84.1% of traded shares were kept for delivery over the last 10 sessions, against 78.3% over the last 60.
Latest results: a net profit of ₹1 cr for the quarter ended Jun 2026 (+13.0% on the same quarter a year earlier).
A description of the data, not a recommendation.
Key figures
Growth
| Revenue (last 12 months) | ₹57 cr |
| Net profit (last 12 months) | ₹0 cr |
| Sales growth, 3 years (yearly) | 4.5% |
| Profit growth, 3 years (yearly) | -73.0% |
At a glance
Promoters 40.1% (-0.5 pts in a year), pledged 87.2%, institutions 0.0%.
P/E 1520.2, dividend yield 0.0%. Price relative to earnings and book value (low is cheaper, not better).
ROE 0.1%, ROCE -0.3%, operating margin 0.5%: how much profit it earns on the money it uses.
Debt/equity 0.26, Profit growth -73.0% and sales growth 4.5% a year over 3 years.
Ratings use fixed thresholds on the latest reported figures. They describe the numbers and are not a recommendation.
Strengths and limitations
None flagged by these rules.
- Low return on equity (0.1%).
- Thin operating margin (0.5%).
- Profit fell 73.0% a year over 3 years.
- Slow sales growth (4.5% a year over 3 years).
- Promoters have pledged 87.2% of their shares.
Picked automatically from the latest reported figures with fixed rules; check the company's filings before relying on them.
Latest results in brief (Q1 FY27)
LOTUSEYE Q1 FY27 results (standalone figures, as filed on NSE).
Revenue was ₹17.06 crore, up 26.2% YoY and up 25.3% QoQ.
Net profit was ₹0.61 crore, up 13% YoY and a turn to profit from a loss last quarter.
Operating margin was 17.3% (10.9% a year ago).
EPS was ₹0.3, up 15.4% YoY and positive against a negative EPS last quarter.
LOTUSEYE के Q1 FY27 नतीजे (स्टैंडअलोन आंकड़े, NSE पर दाखिल)।
राजस्व: ₹17.06 करोड़; पिछले साल की तुलना में 26.2% की बढ़त, पिछली तिमाही की तुलना में 25.3% की बढ़त।
शुद्ध मुनाफ़ा: ₹0.61 करोड़; पिछले साल की तुलना में 13% की बढ़त, पिछली तिमाही के घाटे से मुनाफ़े में आया।
ऑपरेटिंग मार्जिन: 17.3% (एक साल पहले 10.9%)।
EPS: ₹0.3; पिछले साल की तुलना में 15.4% की बढ़त, पिछली तिमाही के ऋणात्मक EPS से धनात्मक हुआ।
LOTUSEYEના Q1 FY27 પરિણામો (સ્ટેન્ડઅલોન આંકડા, NSE પર ફાઇલ કરેલા).
આવક (રેવન્યુ): ₹17.06 કરોડ; ગયા વર્ષની સરખામણીએ 26.2% વધારો, ગયા ક્વાર્ટરની સરખામણીએ 25.3% વધારો.
ચોખ્ખો નફો: ₹0.61 કરોડ; ગયા વર્ષની સરખામણીએ 13% વધારો, ગયા ક્વાર્ટરની ખોટમાંથી નફામાં આવી.
ઓપરેટિંગ માર્જિન: 17.3% (એક વર્ષ પહેલાં 10.9%).
EPS: ₹0.3; ગયા વર્ષની સરખામણીએ 15.4% વધારો, ગયા ક્વાર્ટરના નકારાત્મક EPSથી હકારાત્મક થઈ.
Written from the filed numbers. Not a recommendation.
Smart-money activity
29/100 · Neutral over the last ~60 sessions, data 2026-10-30
- Delivery vs usual 24/30: Delivery 83.9% over the last 20 sessions vs 76.2% in the 40 before (1.1x); shares delivered per day 2.02x usual; 4 delivery-spike days (3x usual shares delivered, 40%+ delivery) in the last 20 sessions.
- Bulk/block deals 0/20: No bulk or block deals in the last 90 days.
- Insider / SAST buys 0/15: No insider buy or SAST acquisition filings in the last 90 days. Insider sells are not collected by the site, so only buy filings count.
- Mutual fund holding 0/15: No mutual fund scheme lists this stock. Latest monthly portfolios only (top 60 holdings per scheme); month-on-month change is not stored.
- Accumulation evidence 0/15: No accumulation evidence row (only saved-scan stocks have one; 0 points).
- Promoter pledges 5/5: No promoter pledge filings in 90 days.
A description of recorded activity (delivery, deals, insider buys, fund holding, pledges), not a recommendation. Today's most active stocks.
Story so far
● Results
- 10 Aug 26Results Q1 FY27 results: profit +13.0% YoY +0.8% next session
- 26 May 26Results Q4 FY26 results: turned to loss vs a year ago -0.7% next session
- 11 Feb 26Results Q3 FY26 results: loss widened vs a year ago -1.1% next session
- 12 Nov 25Results Q2 FY26 results: profit +20.0% YoY -2.3% next session
- 12 Aug 25Results Q1 FY26 results: profit −12.9% YoY +3.4% next session
- 29 May 25Results Q4 FY25 results: profit +1150.0% YoY -1.4% next session
- 12 Feb 25Results Q3 FY25 results: turned to loss vs a year ago -6.4% next session
- 12 Nov 24Results Q2 FY25 results: profit −88.2% YoY -1.3% next session
From official exchange filings and NSE data. How the price moved after an event describes the past, not what comes next.
Quarterly results (standalone)
| Quarter | Revenue | Net profit | Profit YoY | Op. margin | EPS ₹ |
|---|---|---|---|---|---|
| Jun 2026 | ₹17 cr | ₹1 cr | +13.0% | 17.3% | 0.3 |
| Mar 2026 | ₹14 cr | ₹-0 cr | -228.0% | 3.5% | -0.15 |
| Dec 2025 | ₹14 cr | ₹-0 cr | — | 4.8% | -0.13 |
| Sept 2025 | ₹13 cr | ₹0 cr | +20.0% | 5.9% | 0.06 |
Shareholding trend
| Holder | Sept 2026 | Jun 2026 | Mar 2026 | Dec 2025 |
|---|---|---|---|---|
| Promoters | 40.14% | 40.14% | 40.14% | 39.67% |
| Foreign institutions (FII) | — | — | 0.00% | 0.01% |
| Domestic institutions (DII) | 0.02% | 0.02% | 0.02% | 2.46% |
| Mutual funds | — | — | — | — |
| Retail investors | 13.81% | 13.32% | 13.55% | 13.51% |
| Number of shareholders | 9,572 | 9,627 | 9,939 | 10,241 |
Common questions
What was Lotus Eye Hospital And Institute Ltd's latest quarterly profit?
Lotus Eye Hospital And Institute Ltd reported a net profit of ₹1 cr for the quarter ended Jun 2026 (+13.0% on the same quarter a year earlier), on revenue of ₹17 cr.
How much do promoters hold in Lotus Eye Hospital And Institute Ltd?
Promoters held 40.14% of Lotus Eye Hospital And Institute Ltd at the end of Sept 2026, with 87.15% of promoter shares pledged.
Is Lotus Eye Hospital And Institute Ltd debt-free?
Its latest reported debt-to-equity ratio is 0.26.
What is Lotus Eye Hospital And Institute Ltd's P/E ratio?
About 1,520.2, based on the last 12 months' earnings and a price of ₹109.15 (data 2026-10-31).
What is the 52-week high and low of Lotus Eye Hospital And Institute Ltd?
The 52-week high is ₹147 and the 52-week low is ₹97.59.
Compared with similar companies
| Company | Price | Market cap | P/E | P/B | ROE | ROCE | Debt/eq. | 1-yr return |
|---|---|---|---|---|---|---|---|---|
| Lotus Eye Hospital And Institute Ltd | ₹109.15 | ₹221 cr | 1,520.2 | — | 0.1% | -0.3% | 0.26 | -9.0% |
| Gaudium IVF & Women Health Ltd. | ₹105.86 | ₹770 cr | — | — | 24.7% | 35% | 0.16 | +27.5% |
| CHANDAN HEALTHCARE LIMITED | ₹235 | ₹575 cr | — | — | 18.4% | 23.4% | 0.31 | -33.8% |
| Rays of Belief Limited | ₹245.16 | ₹513 cr | — | — | — | — | — | +2.6% |
| Pramodini Medicare Limited | ₹106.6 | ₹235 cr | — | — | — | — | — | -11.2% |
| Vaidya Sane Ayurved Laboratories Limited | ₹136 | ₹143 cr | 15.9 | 1.6 | 12% | 12% | 0.03 | -48.7% |
Compare LOTUSEYE with GAUDIUMIVF in detail →
The full analysis has the price chart, every quarterly result with YoY/QoQ growth, the balance sheet and cash flow with an accounting red-flag check, shareholding quarter by quarter with big investors, news, filings and bulk/block deals.
Open LOTUSEYE in NSE Scanner →